from the Water Protectors. First. addressing the social determinants of health requires dismantling the upstream systems of power that structure society, such as racial capitalism and settler colonialism.4 Second, working upstream requires a collective, longitudinal pursuit of justice. The movement to resist Line 3 has been organising for 13 years, building restorative communities and germinating relationships of trust among multisectoral coalitions. Third, human and natural ecosystem health is inter-related and we must prioritise addressing climate change as essential health work. Fourth, just as some Water Protectors risk arrest or danger to their bodies, so too must healthcare workers risk confrontation with power holders in our health-care and political systems.

In our efforts to deeply engage with the social determinants of health, Water Protectors, who prevent the destruction of life and assert the sovereignty of Indigenous people, are an exemplar of truly upstream health and healing.

WL is the executive director of Honor the Earth.
All other authors declare no competing interests.

Mary Owen, *Michael Westerhaus, Amy Finnegan, Laalitha Surapaneni, Winona LaDuke west0591@umn.edu

Center of American Indian and Minority Health, University of Minnesota, Duluth, MN, USA (MO); Global Medicine (MW) and Division of General Internal Medicine (LS), University of Minnesota, Twin Cities, MN, USA; University of St Thomas, St Paul, MN, USA (AF); Honor the Earth, MN, USA (WL); Center for International Health, St Paul, MN 55104, USA (MW)

- McKinlay J. The case for refocusing upstream: the political economy of illness.
 In: Conrad P, ed. The sociology of health and illness: critical perspectives, 7th edn. New York, NY: Worth Publishers, 2005; 551–64.
- 2 Schulz LO, Bennett PH, Ravussin E, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006; 29: 1866–71.
- 3 King M, Smith A, Gracey M. Indigenous health part 2: the underlying causes of the health gap. Lancet 2009; 374: 76–85.
- 4 Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav 1995; **35**: 80–94.

Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments

To address COVID-19 vaccine scarcity. Ivan Sisa and colleagues¹ justify placebo-controlled trials in lowincome and middle-income countries (LMICs), arguing that these countries have "less capacity to negotiate and purchase vaccines than do highincome countries" and that the global shortage can be overcome with more vaccine producers coming from such trials. We are concerned that this reasoning sets the wrong precedent because approving such a trial should show that evidence can only be reached with this design.2 Furthermore, LMICs should not ignore the urgent need to increase production and distribution³ of already efficacious vaccines.

In the interest of saving people's lives, vaccine development demands working towards improved capacities on the road from discovery (free of patent restrictions) to manufacturing and equitable distribution. Therefore, clinical trials should be done simultaneously, engaging volunteers and researchers across a broad range of LMICs and high-income countries. Furthermore, study protocols should provide robust assurances that participants will have access to the vaccine when their priority group is eligible in the general population. Finally, emphasis should be made on other pressing issues, such as adopting low dead space syringes to prevent discarding residues, thus improving vaccine volume.4

Ensuring efficacious vaccines are made widely available and at fair cost, when high-income countries are hoarding up to five times what they need⁵ and prices are speculative, would require making alliances with countries (eg, Brazil or India) with the capacity to produce generic vaccines, alongside efficient syringes, and

means of storage and transportation. Notwithstanding, LMICs will need support from additional partners in other regions of the world.

We declare no competing interests.

*Irene Torres, Daniel Lopez-Cevallos, Osvaldo Artaza, Barbara Profeta, JaHyun Kang, Cristiani Vieira Machado irene.torres@octaedro.edu.ec

Fundación Octaedro, Quito 170505, Ecuador (IT); School of Language, Culture, and Society, Oregon State University, Corvallis, OR, USA (DL-C); Facultad de Ciencias de la Salud, Universidad de las Américas, Santiago de Chile, Chile (OA); Fribourg, Switzerland (BP); College of Nursing and Research Institute of Nursing Science, Seoul National University, Seoul, South Korea (JK); Oswaldo Cruz Foundation-Fiocruz, Rio de Janeiro, Brazil (CVM)

- Sisa I, Noblecilla E, Orozco F. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs. Lancet 2021; 397: 878.
- 2 Krause PR, Fleming TR, Longini IM, et al. Placebo-controlled trials of COVID-19 vaccines—why we still need them. N Engl J Med 2021; 384: e2.
- 3 Torres I, Artaza O, Profeta B, Alonso C, Kang J. COVID-19 vaccination: returning to WHO's Health For All. Lancet Glob Health 2020; 8: e1355–56.
- 4 Jara CP, Velloso LA, de Araújo EP. Optimizing COVID-19 vaccine usage. medRxiv 2020; published online Jan 1. https://doi.org/ 10.1101/2021.01.04.21249167 (preprint).
- 5 UN Security Council. Secretary–General calls vaccine equity biggest moral test for global community, as Security Council considers equitable availability of doses. Feb 17, 2021. https://www.un.org/press/en/2021/sc14438. doc.htm (accessed Feb 24, 2021).

Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?

The global COVID-19 vaccine roll-out might be the largest public health exercise ever done. COVAX, the vaccines access pillar of the COVID-19 Tools Accelerator, supported by WHO, UNICEF, and others, expects to deliver two billion doses to 190 countries in 1 year. At present, 13 vaccines have received approval in various jurisdictions. The roll-out provides an opportunity, unparalleled in human history, to learn about vaccines.

For more on **COVAX** see https:// www.gavi.org/covax-facility